Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:03 2024-05-31 EDT			5-day change	1st Jan Change
0.6825 ^USD	+4.10%		+3.41%	-9.78%

05-21	Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	CI
05-14	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Citius Pharmaceuticals, Inc. Appoints Suren Dutia to its Board of Directors

October 08, 2015 at 07:00 am

Citius Pharmaceuticals, Inc. announced that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015. Recently, Mr. Dutia served as an independent director of LifeProof (acquired by Otterbox) and Anvita Health (acquired by Humana). Currently Mr. Dutia serves as an independent director on the boards of Flint Rehabilitation Devices, Nanopore Diagnostics, and Vahan.

Latest news about Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	05-21	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-14	CI
Citius Pharmaceuticals Launches $15 Million Offering	04-26	MT
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	04-11	CI
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	03-18	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	02-14	MT
Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment	02-14	MT
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir	02-14	CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	01-03	DJ
Citius Pharmaceuticals Completes Enrollment in Phase 3 Trial for Mino-Lok	01-02	MT
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters	01-02	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-29	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	12-20	DJ
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR? in Combination with Checkpoint Inhibitor	23-10-31	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	23-10-24	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	23-10-24	MT
Citius Pharmaceuticals to Merge Oncology Unit with TenX Keane Acquisition; Citius Shares Rise	23-10-24	MT
Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee	23-09-25	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	23-09-08	MT
Sector Update: Health Care	23-09-08	MT
Citius Pharmaceuticals Says No Additional Trials Required to Support Biologics License Application for Lymphir	23-09-08	MT
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR	23-09-08	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Sector Update: Health Care Stocks Decline Thursday	23-08-10	MT

Chart Citius Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - Mino-Lok Phase 3 Trial Results Call

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6975 USD

Average target price

4 USD

Spread / Average Target

+473.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CITIUS PHARMACEUTICALS, INC.	-9.78%	123M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research